Patents by Inventor Boudewijn Lodewijk Maria DeJonge

Boudewijn Lodewijk Maria DeJonge has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Combination therapy for treatment of resistant bacterial infections
    Patent number: 10376499
    Abstract: The present invention is directed to combinations of a ?-lactamase inhibitor with sulbactam and, optionally, imipenem/cilastatin. The combinations are useful for the treatment of bacterial infections, including infections caused by drug resistant organisms, including multi-drug resistant pathogens. More particularly, the invention relates to a combination of ?-lactamase inhibitor compound 1: or a pharmaceutically acceptable salt thereof, with sulbactam, or a pharmaceutically acceptable salt thereof, and, optionally, imipenem/cilastatin, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: April 9, 2018
    Date of Patent: August 13, 2019
    Assignee: Entasis Therapeutics Limited
    Inventors: Boudewijn Lodewijk Maria DeJonge, Thomas Francois Durand-Reville, Jeroen Cunera Verheijen, Ruben Tommasi, John Mueller
  • COMBINATION THERAPY FOR TREATMENT OF RESISTANT BACTERIAL INFECTIONS
    Publication number: 20180289681
    Abstract: The present invention is directed to combinations of a ?-lactamase inhibitor with sulbactam and, optionally, imipenem/cilastatin. The combinations are useful for the treatment of bacterial infections, including infections caused by drug resistant organisms, including multi-drug resistant pathogens. More particularly, the invention relates to a combination of ?-lactamase inhibitor compound 1: or a pharmaceutically acceptable salt thereof, with sulbactam, or a pharmaceutically acceptable salt thereof, and, optionally, imipenem/cilastatin, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: April 9, 2018
    Publication date: October 11, 2018
    Inventors: Boudewijn Lodewijk Maria DeJonge, Thomas Francois Durand-Reville, Jeroen Cunera Verheijen, Ruben Tommasi, John Mueller
  • Combination therapy for treatment of resistant bacterial infections
    Patent number: 9968593
    Abstract: The present invention is directed to combinations of a ?-lactamase inhibitor with sulbactam and, optionally, imipenem/cilastatin. The combinations are useful for the treatment of bacterial infections, including infections caused by drug resistant organisms, including multi-drug resistant pathogens. More particularly, the invention relates to a combination of ?-lactamase inhibitor compound 1: or a pharmaceutically acceptable salt thereof, with sulbactam, or a pharmaceutically acceptable salt thereof, and, optionally, imipenem/cilastatin, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: November 17, 2015
    Date of Patent: May 15, 2018
    Assignee: Entasis Therapeutics Limited
    Inventors: Boudewijn Lodewijk Maria DeJonge, Thomas Francois Durand-Reville, Jeroen Cunera Verheijen, Ruben Tommasi, John Mueller
  • COMBINATION THERAPY FOR TREATMENT OF RESISTANT BACTERIAL INFECTIONS
    Publication number: 20180000800
    Abstract: The present invention is directed to combinations of a ?-lactamase inhibitor with sulbactam and, optionally, imipenem/cilastatin. The combinations are useful for the treatment of bacterial infections, including infections caused by drug resistant organisms, including multi-drug resistant pathogens. More particularly, the invention relates to a combination of ?-lactamase inhibitor compound 1: or a pharmaceutically acceptable salt thereof, with sulbactam, or a pharmaceutically acceptable salt thereof, and, optionally, imipenem/cilastatin, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: November 17, 2015
    Publication date: January 4, 2018
    Inventors: Boudewijn Lodewijk Maria DeJonge, Thomas Francois Durand-Reville, Jeroen Cunera Verheijen, Ruben Tommasi, John Mueller